SGTX - Sigilon Therapeutics' SIG-007 an Orphan Drug in U.S.

The FDA has granted Orphan Drug Designation to Sigilon Therapeutics' (SGTX) SIG-007 for the treatment of Fabry disease, a progressive, lysosomal disease.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.Sigilon has initiated several IND enabling studies with plans to file four INDs within the next 12-24 months, which includes SIG-007 in patients with Fabry disease. Fabry disease is caused by AGAL deficiency and the accumulation of certain substrates within a patient’s cells, which contribute to multi-organ complications.

For further details see:

Sigilon Therapeutics' SIG-007 an Orphan Drug in U.S.